Using PD-1 and TRBC1 combined with pan-T cell antibodies can make a precise diagnosis of AITL and also sensitively monitor minimal residual disease regardless of the antigenic drift of the neoplastic T cells. Here, TRBC1 is linked to angioimmunoblastic T-cell lymphoma.